Antibody composition with altered Fab sialylation
The present invention relates to a population of antibodies enriched from an antibody preparation, wherein the enriched population of antibodies has an altered amount of sialylation in the Fab region of the antibodies as compared to the antibody preparation prior to enrichment. Furthermore, the present invention relates to a method of enriching a population of antibodies from an antibody preparation, wherein the enriched population of antibodies has an altered amount of sialylation in the Fab region of the antibodies as compared to the antibody preparation prior to enrichment. The present invention also relates to the population of antibodies of the invention for use in medicine, a pharmaceutical composition comprising the populations of antibodies of the invention and the use of the population of antibodies of the invention in the prevention and/or treatment of atherosclerosis, cancer and infections such as bacterial, viral or fungal infections.
1. A method of treating an inflammatory condition in a patient in need thereof, comprising administering an immunoglobulin G preparation obtained from blood plasma to the patient,
wherein the preparation is enriched for immunoglobulin G molecules having an increased amount of sialylation, wherein the increase is greater in the Fab region than in the Fc region, as compared to an immunoglobulin G preparation obtained from blood plasma prior to enrichment,
and wherein the inflammatory condition is systemic lupus erythematosus (SLE), antiphospholipid syndrome, Kawasaki disease, a skin blistering disease, dermatomyositis, or polymyositis.
2. The method of claim 1 , wherein the immunoglobulin G preparation is for intravenous administration (IVIG) or subcutaneous administration (SCIG).
3. The method of claim 1 , wherein the inflammatory condition is SLE.
4. The method of claim 1 , wherein the immunoglobulin G preparation is enriched for immunoglobulin G molecules having an increased amount of sialylation in the Fab region by subjecting the immunoglobulin G preparation to chromatography with a Sambucus nigra agglutinin affinity chromatography matrix.
5. The method of claim 4 , wherein the Sambucus nigra agglutinin affinity chromatography matrix is selective for Fab sialylation over Fc sialylation.
6. The method of claim 5 , wherein the Sambucus nigra agglutinin affinity chromatography is performed at a basic pH at which the matrix selectively binds sialic acid residues in the Fab region of the immunoglobulin G molecules.